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months, 95% CI: 4.5–7.0) than patients lacking CTC (PFS 10.7 
months, 95% CI: 6.9–14.4, p < 0.001; OS 13.3 months, 95% CI: 
8.0–18.6, p = 0.003). Alterations in the marker profile during 
the course of chemotherapy were not predictive of clinical 
outcome or response to therapy. Yet, a favorable clinical re-
sponse depended significantly on CTC negativity (p = 0.03). 
 Conclusion: Our data suggest that the presence of CTC is a 
major predictor of outcome in patients with gastric and gas-
troesophageal malignancies.  © 2015 S. Karger AG, Basel 
 Background 
 Gastric cancer, amounting to approximately 1 million 
new cases per year, is still the fourth most common cancer 
worldwide, with great gender and geographic differences 
in incidence. Adenocarcinomas of the gastroesophageal 
junction possess a lower but rising incidence  [1] . Despite 
advances in diagnosis and treatment, the prognosis for 
these cancer patients is dismal, with a 5-year survival rate 
below 27% for all stages, making this cancer the second 
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 Abstract 
 Objective: We aimed to assess the prognostic value of cir-
culating tumor cells (CTC) in patients with advanced gas-
tric and gastroesophageal adenocarcinomas.  Methods: The 
presence of CTC was evaluated in 62 patients with advanced 
gastric and gastroesophageal adenocarcinomas before sys-
temic therapy and at follow-up through immunomagnetic 
enrichment for mucin 1- and epithelial cell adhesion mole-
cule (EpCAM)-positive cells, followed by real-time RT-PCR of 
the tumor-associated genes  KRT19 ,  MUC1 ,  EPCAM ,  CEACAM5 
and  BIRC5 .  Results: The patients were stratified into groups 
according to CTC detection (CTC negative: with all marker 
genes negative; CTC positive: with at least 1 of the marker 
genes positive). Patients who were CTC positive at baseline 
had a significantly shorter median progression-free survival 
(PFS; 3.5 months, 95% CI: 2.9–4.2) and overall survival (OS; 5.8 
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most common cause of cancer-related death worldwide 
 [2] . This is primarily due to a long asymptomatic course 
and usually diagnosis at an advanced stage, precluding 
curative resection. Current prognostic assessment of both 
cancers is mainly based on morphological criteria catego-
rized in the International Union against Cancer Tumor-
Node-Metastasis (TNM) staging system  [3] and the Lau-
rén classification  [4] . In early-stage gastric cancer, endo-
scopic ultrasound aides in decisions for immediate 
resection or neoadjuvant chemotherapy  [5] . However, 
this evaluation cannot address the molecular and genetic 
heterogeneity of the cancer, precluding an accurate as-
sessment of the individual patient’s prognosis. Over the 
last few years, analysis of human epidermal growth factor 
receptor 2 (HER2/neu) gene expression has been estab-
lished as a predictive tool in a first step towards a targeted 
therapy for these cancers  [6] . However, there is an urgent 
need to develop more broadly applicable parameters in 
order to improve outcome prediction and therapy moni-
toring of patients. While back in 1869 Ashworth  [7] pro-
vided a first report on cells in peripheral blood that re-
sembled those discovered in the primary tumor, refined 
technologies developed in the last decades have unam-
biguously demonstrated the presence of circulating tu-
mor cells (CTC) in the peripheral blood of patients with 
gastric cancer  [8, 9] .
 We previously conducted studies demonstrating that 
immunomagnetic enrichment followed by real-time 
PCR analysis of the tumor-associated genes keratin 19 
 (KRT19) , mucin 1  (MUC1) , epithelial cell adhesion mol-
ecule  (EPCAM) , carcinoembryonic antigen-related cell 
adhesion molecule 5  (CEACAM5) and survivin  (BIRC5) 
can be used to detect CTC as independent predictors of 
progression-free survival (PFS) in patients with pancre-
atic  [10] and colon cancer  [11] .
 Here, we present a study using this unique technique 
for the first time to investigate the role of CTC as a prog-
nostic marker in patients with advanced-stage cancer of 
the stomach and the esophagogastric junction.
 Subjects and Methods 
 Patient Selection 
 Between January 2010 and December 2011, all patients with 
histologically proven advanced or metastatic adenocarcinomas of 
the stomach and the gastroesophageal junction at the Department 
of Internal Medicine of Chemnitz Central Hospital, one of the 
largest tertiary care centers in Germany, were enrolled in the study. 
The cohort included patients initiating a first-line or a second-line 
chemotherapy and displaying an Eastern Cooperative Oncology 
Group performance status (ECOG PS) of 0–2, but excluded pa-
tients with previous or secondary carcinoma and severe infection. 
The patients’ characteristics are detailed in  table 1 .
 The therapy regimes were FLO (5-fluorouracil, leucovorin and 
oxaliplatin), FLOT (5-fluorouracil, leucovorin, oxaliplatin and 
docetaxel), TOGA (trastuzumab, 5-fluorouracil and cisplatin), 
PLF (5-fluorouracil, leucovorin and paclitaxel), DCF (docetaxel, 
cisplatin, 5-fluorourcil and leucovorin), FUFIRI (5-fluorouracil, 
leucovorin and irinotecan) and AIO (5-fluorouracil and leucovo-
rin).
 Before starting new systemic treatment, the patients underwent 
a clinical evaluation including a physical examination, laboratory 
analyses, computed tomography scanning of the abdomen and the 
chest and a baseline 2 × 10 ml peripheral blood draw for CTC 
analysis. In order to prevent contamination of epithelial cells, we 
discarded the first 10 ml of blood and used the following 10 ml of 
blood for CTC analysis. Along with clinical follow-up, another 
blood draw was performed for follow-up CTC analysis. The stage 
of disease was reevaluated after 10–14 weeks depending on the 
treatment regimen using the Response Evaluation Criteria in Solid 
Tumors (RECIST)  [12] and classified as complete response (CR), 
partial response (PR), stable disease (SD) or progressive disease 
(PD). We subdivided the patients into a group with non-PD (in-
cluding CR/PR/SD) and one with PD or death. Surviving patients 
were followed up for at least 12 months. The study was approved 
by the local ethics committee and conducted in accordance with 
the principles of the Declaration of Helsinki. Written informed 
consent was obtained from all patients.
 CTC Isolation from Blood Samples, mRNA Isolation and 
DNA Synthesis 
 CTC were isolated from peripheral blood by using 200 μl im-
munomagnetic Dynabeads ® (Invitrogen, Karlsruhe, Germany) 
coated with the antibodies BM7 and VU1D9 (targeting mucin 1 
and EpCAM, respectively). After performing ablution (5 times) 
with phosphate-buffered salt solution, the obtained mucin 1 and 
EpCAM-positive cells were lysed in 400 μl Tris-HCl buffer. The 
cell lysates were stored at –85  °  C until further processing.
 The following mRNA isolation was performed with the Dyna-
beads ® mRNA DIRECT Kit according to the manufacturer’s 
guidelines. For reverse transcription of the purified mRNA into 
cDNA, we used Sensiscript ® Reverse Transcriptase (Qiagen, 
Hilden, Germany) in combination with Dynabeads ® oligo(dT)25 
(Invitrogen, Germany).
 The resulting cDNA was the template for tumor cell detection 
and characterization by real-time PCR. Using real-time RT-PCR, 
epithelial tumor-associated genes found to be expressed in adeno-
carcinomas of the stomach and the gastroesophageal junction 
( KRT19 ,  MUC1  [13] ,  EPCAM  [14] ,  CEACAM5  [15] and  BIRC5 
 [16] ) were analyzed.
 Primers were selected from the Universal ProbeLibrary ( ta-
ble 2 ) and were designed to be intron spanning (exon specific) so 
as to eliminate reactivity with genomic DNA. We used the ampli-
fication of  ACTB (primers: forward 5 ′ -GAAGAGCCAAGGA-
CAGGTAC-3 ′ ; reverse 5 ′ -CAACTTCATCCACGTTCACC-3 ′ ) as 
the internal control as well as to verify the integrity of the RNA and 
the quality of the samples. PCR amplifications were performed on 
a Rotor-Gene device in a total volume of 25 μl containing 12.5 μl 
reaction buffer (MESA FAST qPCR MasterMix Plus for SYBR ® 
Assay; Eurogentec, Köln, Germany), 0.1 μl of each primer, 2 μl of 
cDNA and 10.3 μl of RNase-free H 2 O. We used the following ther-
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 Table 1.  Demographic and clinical characteristics of the patients
Evaluated patients 62
Median age at baseline (range), years 64 (47 – 81)
Sex
Female 23 (37)
Male 39 (63)
Baseline ECOG PS
0 26 (41.9)
1 27 (43.6)
2 9 (14.5)
Primary tumor
AEG I 14 (22.6)
AEG II 9 (14.5)
AEG III 2 (3.2)
AEG (all) 25
Gastric cancer 37 (59.7)
Stage at primary diagnosis
III 4 (6.5)
IV 58 (93.5)
Laurén type (gastric cancer only)
Intestinal 17 (45.9)
Diffuse 20 (54.1)
Grading
G1 7 (11.3)
G2 19 (30.6)
G3 28 (45.2)
G4 8 (12.9)
Line of therapy
First 55 (88.7)
Second 7 (11.3)
Tumor size
T1 3 (4.8)
T2 9 (14.5)
T3 29 (46.8)
T4 21 (33.9)
Node
N0 4 (6.5)
N1 25 (40.3)
N2 26 (41.9)
N3 7 (11.3)
Site of metastasis
Liver 22 (35.5)
Lymph node 29 (46.8)
Peritoneal 26 (41.6)
Lung 10 (16.1)
Adnexa 6 (9.7)
Bone 4 (6.5)
Spleen 1 (1.6)
Her2 status
Positive 5 (13.5)
Negative 15 (40.5)
Not tested 17 (45.9)
Type of therapy at study entry
5-Fluorouracil used 57 (91.9)
Cisplatin used 19 (30.7)
Oxaliplatin used 33 (53.2)
Docetaxel used 29 (46.8)
Irinotecan used 6 (9.7)
Trastuzumab used (TOGA) 2 (3.2)
Data are presented as n (%) unless specified otherwise. AEG = 
Adenocarcinoma of the esophagogastric junction.
 Table 2. Intron-spanning primer pairs for each selected gene
Marker NM reference Primer sequence Location Product size, bp
KRT19 NM_002276.2 forward: GCCACTACTACACGACCATCC 525 – 545, exon 1 126
reverse: CAAACTTGGTTCGGAAGTCAT 650 – 630, exon 2/3
MUC1 NM_002456.4 forward: TCGTAGCCCCTATGAGAAGG 795 – 814, exon 7/8 71
reverse: CCACTGCTGGGTTTGTGTAA 865 – 846, exon 8
EPCAM NM_002354.2 forward: CGTCAATGCCAGTGTACTTCA 448 – 508, exon 2 88
reverse: TTTCTGCCTTCATCACCAAA 575 – 553, exon 3
CEACAM5 NM_004363.2 forward: ACCACAGTCACGACGATCAC 1052 – 1071, exon 4 78
reverse: CTCCACGGGGTTGGAGTT 1129 – 1112, exon 5
BIRC5 NM_001168.2 forward: GCCCAGTGTTTCTTCTGCTT 284 – 303, exon 2 86
reverse: CCGGACGAATGCTTTTTATG 369 – 350, exon 3
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mocycler protocol for real-time PCR: initial 5 min denaturation at 
95  °  C; 40 cycles carried out by denaturation at 95  °  C for 5 s, anneal-
ing at 59  °  C for 20 s and extension at 72  °  C for 12 s. Further techni-
cal details, and in particular the calculation of the accuracy, preci-
sion, linearity and reproducibility of the PCR procedure, have been 
described in a previous study  [17] . Considering the limitations 
presented by relative and absolute quantification, we used real-
time RT-PCR to verify the presence of the gene rather than to 
quantify it precisely.
 According to the results obtained in our previous investigation, 
the Cq cutoff below which a marker gene is considered to be 
 positive was defined as 36.0 for  KRT19 , 37.1 for  MUC1 , 36.0 for 
 EPCAM , 37.8 for  CEACAM5 and 35.0 for  BIRC5 . A sample was 
considered to be CTC positive when at least 1 of the marker genes 
was positive.
 Statistical Analysis 
 PFS was measured as the time elapsed between the baseline 
CTC assessment (at initiation of the therapy) and the first docu-
mentation of progress, death or the last follow-up (in the event that 
no progression and/or death occurred during the follow-up peri-
od). Overall survival (OS) was measured as the time elapsed be-
tween the baseline CTC assessment and either the date of death or 
the last follow-up (in case no death occurred during the follow-up 
period).
 PFS and OS were compared between the CTC-positive and the 
CTC-negative group with the Kaplan-Meier method, and differ-
ences were tested with the log-rank test. Furthermore, a multivar-
iate Cox regression was calculated. The distribution of patients 
with positive and negative CTC and the clinical response was com-
pared using Fisher’s exact test.
 All tests were two-sided, and the significance level required was 
at p < 0.05. Statistical analyses were carried out using SPSS (version 
19.0; SPSS, Chicago, Ill., USA).
 Results 
 Patient Characteristics 
 Between January 2010 and December 2011, a total of 
62 patients (39 men and 23 women; 37 with gastric and 
25 with gastroesophageal cancer) were enrolled. The me-
dian age at first blood draw was 64 years (range 47–81). 
 Table  1 provides detailed information on the patients’ 
baseline characteristics.
 After a median follow-up of 17.2 months with a range 
of 1–35 months (95% CI: 14.2–20.3), 61 of the 62 patients 
had progressed and 55 had died. Median PFS from base-
line was 5.9 months (95% CI: 2.8–6.9), and median OS 
was 7.6 months (95% CI: 5.5–9.8).
 CTC at Baseline 
 At baseline, 69.4% of the patients tested positive for 
CTC (detection of at least 1 tumor-associated transcript). 
The detection rate for each marker was as follows: 43.4% 
for  KRT19 , 51.6% for  MUC1 , 50.0% for  EPCAM , 27.4% 
for  CEACAM5 and 24.2% for  BIRC5 . As previously de-
scribed, the healthy controls (n = 40) did not show any 
amplification of the markers genes  [17] .
 CTC at Follow-Up 
 At follow-up, 85.5% of the remaining 61 patients 
tested positive for CTC (detection of at least 1 tumor-
associated transcript). The detection rate for each 
marker was as follows: 37.1% for  KRT19 , 67.7% for 
 MUC1 , 59.7% for  EPCAM , 22.6% for  CEACAM5 and 
27.4% for  BIRC5 .
 CTC as a Prognostic Marker 
 Identifying CTC at baseline strongly predicted a sig-
nificantly shorter median PFS (3.5 months, 95% CI: 2.9–
4.2) and OS (5.8 months, 95% CI: 4.5–7.0) as compared 
with patients lacking CTC at baseline (median PFS: 10.7 
months, 95% CI: 6.9–14.4, log-rank p < 0.001; median OS: 
13.3 months, 95% CI: 8.0–18.6, log-rank p = 0.003). The 
corresponding Kaplan-Meier curves are shown in  figures 
1 and  2 .
 As described above, a sample was considered to be 
CTC positive when at least 1 of the 5 marker genes was 
positive. We also examined whether instead of a 5-mark-
er panel, the sole detection of a single marker or a combi-
nation of 2 or 3 markers has prognostic value. Detection 
of the transcripts  KRT19 (p = 0.025),  MUC1 (p = 0.007) 
or  EPCAM (p = 0.009) alone is sufficient to predict a sig-
nificantly shorter PFS, while the sole detection of the 
transcripts  CEACAM5 or  BIRC5 could not predict sig-
nificant effects on PFS. Regarding a combination of 2 
markers (positive if at least 1 of the 2 marker genes was 
positive), we were able to demonstrate that all possible 
combinations of 2 markers predicted a significantly 
shorter PFS ( table 3 ).
 When calculating OS, it could be shown that only the 
sole detection of the transcript  CEACAM5 (p = 0.006) was 
associated with a significantly shorter OS, while the sole 
detection of the transcripts  KRT19 ,  MUC1 ,  EPCAM or 
 BIRC5 was not associated with a significantly shorter OS. 
Regarding a combination of 2 markers (positive if at least 
1 of the 2 marker genes was positive), we were able to 
demonstrate that all possible combinations of 2 markers, 
except the combination of  EPCAM-BIRC5 (p = 0.05), pre-
dicted a significantly shorter OS.
 Predictors of PFS and OS 
 Univariate Cox regression analysis demonstrated 
ECOG PS, type of therapy as well as CTC detection (at 
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baseline and follow-up) to be significantly associated with 
both PFS and OS. No significance was found for degree 
of differentiation of the tumor, site of metastasis, line of 
therapy, initial involvement of lymph nodes or age. The 
univariately significant associated factors were included 
in a multivariate Cox regression analysis. Expression of 
the tumor-associated marker genes of CTC, irrespective 
of their nature, at baseline as well as at follow-up re-
mained a strong and independent predictor of PFS and 
OS ( table 4 ). However, this analysis must be interpreted 
with caution because the number of covariates exceeds 
the number of events necessary to get a robust estimate of 
the regression coefficients.
 Correlation between CTC and Radiographic Response 
 Sixty-one of the 62 patients underwent follow-up im-
aging in order to be assessed by the RECIST at weeks 
10–14 (mean: week 12). One of the patients (1.6%) had 
a PR, 33 (54.1%) SD and 27 (44.6%) PD. All 27 patients 
with PD (100%) had tested positive for CTC at the be-
ginning of the study. The sensitivity and specificity of 
CTC detection were 100 and 22.85%, respectively, and 
the positive and negative predictive values for the indi-
vidual prognosis were 49 and 100%, respectively. Alter-
ations within the marker profile during the course of 
chemotherapy were not associated with clinical out-
come or response to therapy. Yet, a favorable clinical 
response depended significantly on CTC negativity (p = 
0.03, Fisher’s exact test;  table 5 ). This can be explained 
by the fact that our CTC study was based on the pres-
ence/absence of CTC rather than on the use of real-time 
PCR for quantification of these cells. Therefore, altera-
tions in the marker profiles could not be precisely as-
sessed.
 Discussion 
 We demonstrated that a combination of immunomag-
netic separation of CTC followed by a real-time RT-PCR 
analysis of  KRT19 ,  MUC1 ,  EPCAM ,  CEACAM5 and 
 BIRC5 can serve as a prognostic tool for PFS and OS in 
patients with advanced cancer of the stomach and the 
gastroesophageal junction.
 Despite an increased understanding of the pathomech-
anisms of carcinogenesis and advances in diagnosis and 
0
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 Fig. 1. Kaplan-Meier plot of PFS in advanced gastric and gastro-
esophageal cancer patients with positive versus negative CTC at 
baseline. 
 Fig. 2. Kaplan-Meier plot of OS in advanced gastric and gastro-
esophageal cancer patients with positive versus negative CTC at 
baseline. 
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treatment, the overall prognosis remains dismal and se-
lecting the most beneficial therapy for advanced gastric 
and gastroesophageal adenocarcinomas is challenging. 
Although patients with metastatic gastric cancer have 
benefited from the introduction of the first predictive 
marker erbB-2  [18] , there is an urgent need for other 
prognostic and predictive molecular markers to better 
elucidate the heterogeneity of gastric cancer. The addi-
tion of CTC analysis to the standard evaluation of these 
cancers could lead to more reliable and accurate disease 
prediction and help identify possible novel therapeutic 
targets.
 Currently, a variety of methods for detecting CTC 
from peripheral blood are available, including flow cy-
tometry, immunomagnetic separation, CTC microchip 
technology, PCR-based approaches and the FDA-ap-
proved and widely accepted CellSearch ®  [19] . All of these 
techniques have distinct advantages and limitations. In 
a PFS
CTC 
detection
Estimator,
months
Standard
error
95% CI log-rank
lower limit upper limit sig. (p) χ2
Sole marker
KRT19 neg. 7.41 1.02 5.40 9.42 0.025 5.05
pos. 4.54 0.56 3.44 5.64
MUC1 neg. 7.57 2.51 2.66 12.48 0.007 7.27
pos. 3.90 0.54 2.85 4.95
EPCAM neg. 7.41 0.96 5.52 9.30 0.009 6.856
pos. 3.90 0.40 3.12 4.68
CEACAM5 neg. 7.34 1.60 4.20 10.48 0.055 3.684
pos. 3.87 0.74 2.42 5.32
BIRC5 neg. 5.98 1.85 2.35 9.61 0.239 1.389
pos. 3.90 1.06 1.83 5.97
Combination of at least 2 markers (at least 1 positive)
MUC1-EPCAM neg. 9.64 1.73 6.24 13.04 0.001 12.057
pos. 3.90 0.42 3.07 4.73
KRT19-EPCAM neg. 7.71 1.43 4.91 10.51 0.001 11.088
pos. 3.90 0.22 3.46 4.34
KRT19-BIRC5 neg. 7.71 1.32 5.13 10.29 0.002 9.215
pos. 3.91 0.37 3.18 4.64
MUC1-BIRC5 neg. 7.71 1.57 4.64 10.78 0.001 11.41
pos. 3.80 0.42 2.98 4.62
EPCAM-BIRC5 neg. 7.57 0.33 6.92 8.22 0.004 8.319
pos. 3.90 0.41 3.09 4.71
CEACAM5-BIRC5 neg. 7.41 0.59 6.25 8.57 0.009 6.901
pos. 3.87 0.34 3.21 4.53
KRT19-MUC1 neg. 9.71 1.62 6.53 12.89 0.000 12.682
pos. 3.90 0.22 3.46 4.34
KRT19-CEACAM5 neg. 7.71 1.32 5.13 10.29 0.004 8.213
pos. 4.16 0.38 3.41 4.91
MUC1-CEACAM5 neg. 7.71 1.57 4.64 10.78 0.001 10.425
pos. 3.87 0.31 3.27 4.47
EPCAM-CEACAM5 neg. 7.71 1.93 3.93 11.49 0.003 9.087
pos. 3.90 0.44 3.04 4.76
KRT19-MUC1-EPCAM neg. 9.74 1.13 7.53 11.95 0.001 15.493
pos. 3.90 0.37 3.18 4.62
All markers (at least 1 positive) pos. 10.70 2.13 6.90 14.40 0.001 16.414
neg. 3.50 0.41 2.90 4.20
total 4.82 1.03 2.79 6.85
 Table 3. PFS and OS prediction according to different models of tumor-associated transcript positivity
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contrast, our assay combines the advantage of dual (mu-
cin 1- and EpCAM-based) immunomagnetic enrichment 
of disseminated tumor cells and subsequent real-time 
RT-PCR of a spectrum of cancer-associated transcripts. 
Our dual immunomagnetic enrichment procedure was 
based on the specific antibodies VU1D9 and BM7 captur-
ing EpCAM and mucin 1 antigens, which are highly ex-
pressed in gastric  [20, 21] and esophageal  [22, 23] cancer 
tissue.
 However, it has been proven that all EpCAM-based 
enrichment systems share the limitation that they could 
miss CTC  [24–26] or capture other than cancer cells. By 
b OS
CTC 
detection
Estimator,
months
Standard
error
95% CI  log-rank
lower limit upper limit si g. (p) χ2
Sole marker
KRT19 neg. 8.75 0.86 7.06 10.44 0.078 3.102
pos. 6.21 0.83 4.58 7.84
MUC1 neg. 9.71 1.93 5.93 13.49 0.102 2.680
pos. 6.24 0.79 4.70 7.78
EPCAM neg. 9.64 1.59 6.53 12.75 0.108 2.577
pos. 5.44 0.74 4.00 6.88
CEACAM5 neg. 9.64 0.99 7.70 11.59 0.006 7.438
pos. 5.44 0.66 4.15 6.73
BIRC5 neg. 8.52 1.32 5.93 11.11 0.081 3.054
pos. 6.31 0.68 4.99 7.64
Combination of at least 2 markers (at least 1 positive)
MUC1-EPCAM neg. 11.87 2.24 7.47 16.27 0.021 5.295
pos. 5.98 0.64 4.72 7.24
KRT19-EPCAM neg. 11.34 2.44 6.57 16.12 0.027 4.894
pos. 5.44 0.72 4.04 6.85
KRT19-BIRC5 neg. 9.71 1.84 6.11 13.31 0.009 6.729
pos. 5.44 0.63 4.21 6.67
MUC1-BIRC5 neg. 11.34 2.10 7.22 15.46 0.012 6.261
pos. 5.44 0.70 4.07 6.81
EPCAM-BIRC5 neg. 9.97 2.32 5.42 14.52 0.050 3.844
pos. 5.44 0.76 3.95 6.93
CEACAM5-BIRC5 neg. 9.97 2.02 6.01 13.93 0.001 10.381
pos. 5.44 0.77 3.94 6.94
KRT19-MUC1 neg. 11.87 2.42 7.12 16.62 0.031 4.665
pos. 6.21 0.58 5.07 7.35
KRT19-CEACAM5 neg. 9.71 1.85 6.08 13.34 0.024 5.130
pos. 6.21 0.57 5.09 7.33
MUC1-CEACAM5 neg. 11.34 2.10 7.22 15.46 0.021 5.288
pos. 5.98 0.68 4.65 7.31
EPCAM-CEACAM5 neg. 11.34 1.88 7.66 15.02 0.049 3.875
pos. 5.98 0.61 4.79 7.17
KRT19-MUC1-EPCAM neg. 13.18 1.14 10.95 15.41 0.007 7.334
pos. 5.98 0.56 4.89 7.07
All markers (at least 1 positive) pos. 13.30 1.05 11.12 15.24 0.003 7.183
neg. 5.80 0.61 5.01 7.41
total 7.57 1.00 5.61 9.53   
 pos. = Positive; neg. = negative; sig. = significance.
Table 3 (continued)
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selecting an additional antigen such as mucin 1 that is 
ubiquitously and abundantly present on tumor cells  [27] 
but that is absent on cells of hematopoietic origin, we en-
hanced the possibility of successful CTC isolation.
 The obtained and isolated CTC were analyzed for 
transcripts that play an important role in gastric cancer 
biology. High mRNA levels of  BIRC5 (survivin) – a gene 
that encodes an antiapoptotic protein belonging to the 
class of inhibitors of apoptosis proteins – in peripheral 
blood has prognostic value in gastric cancer  [28] . Studies 
using RT-PCR for the detection of mucin 1, keratin 19 
and CEACAM5 in the peripheral blood of patients with 
gastric cancer are heterogeneous and controversial. Al-
though  MUC1  [29] ,  CEACAM5  [30] and, in particular, 
 KRT19  [31] were found to predict postoperative recur-
rence, Bertazza et al.  [28] demonstrated that the latter 2 
markers  (KRT19 and  CEACAM5) did not correlate with 
survival. Using nested RT-PCR, Matsumura et al.  [32] 
 detected EpCAM positivity in the peripheral blood of 
30% of gastric cancer patients without validating them as 
prognostic parameters.
 At baseline, we detected  EPCAM ,  MUC1 ,  KRT19 , 
 CEACAM5 and  BIRC5 in 50, 51.6, 43.4, 27.4 and 24.2% 
of our blood samples, respectively. A total of 69.4% of the 
peripheral blood samples of our patients showed at least 
1 tumor-associated marker on mRNA amplification. This 
high proportion, as compared to most other studies  [33] , 
is due to our patient cohort, which presented exclusively 
with advanced-stage carcinomas. Our results demon-
strate that testing positive for at least 1 of 5 tumor-asso-
ciated marker mRNAs strongly predicts PFS as well as 
OS. This is novel and indicates that the ability of an ad-
 Table 5. CTC and correlation with response assessment by imaging (computed tomography) at follow-up using 
Fisher’s exact test
Non-PD (by RECIST) PD (by RECIST) Fisher’s exact 
p valuetotal CTC neg. CTC pos. total CTC neg. CTC pos.
Patients 34 9 25 27 0 27 0.003
pos. = Positive; neg. = negative.
 Table 4. Multivariate Cox regression analysis for prediction of PFS and OS among univariately significant parameters
Parameters Categories PFS risk from blood draw OS risk from blood draw
pos. neg. HR 95% CI p patients, n HR 95% CI p patients, n
CTC at baseline yes no 4.96 2.2 – 11.2 0.000 62 4.1 1.7 – 9.5 0.001 62
EOCG PS 0/1 2 0.31 0.15 – 0.63 0.001 0.2 0.9 – 0.42 0.000
Oxaliplatin used in regime yes no 5.67 1.8 – 18.2 0.004 5.86 1.9 – 18.6 0.003
Cisplatin used in regime yes no 4.86 1.4 – 15.4 0.014 6.6 1.9 – 23.6 0.004
Docetaxel used in regime yes no 0.4 0.2 – 0.8 0.012 0.66 0.3 – 1.3 0.246
Irinotecan used in regime yes no 3.36 0.8 – 14.2 0.099 6.8 1.5 – 31.8 0.015
Trastuzumab used in regime yes no 1.8 0.2 – 15.4 0.595 2 0.23 – 17 0.531
CTC at follow-up yes no 3.84 1.6 – 9.3 0.003 61 6.5 2.0 – 21.3 0.002 61
EOCG PS 0/1 2 0.28 0.13 – 0.59 0.001 0.21 0.09 – 0.47 0.000
Oxaliplatin used in regime yes no 1.8 0.51 – 6.5 0.359 3.2 0.8 – 12.1 0.094
Cisplatin used in regime yes no 2.01 0.49 – 8.3 0.332 3.4 0.75 – 15.1 0.114
Docetaxel used in regime yes no 0.9 0.45 – 1.8 0.763 0.69 0.33 – 1.4 0.691
Irinotecan used in regime yes no 2.2 0.43 – 11.6 0.345 2.7 0.48 – 14.9 0.265
Trastuzumab used in regime yes no 1.6 0.19 – 13.6 0.669 1.8 0.2 – 14.9 0.611
pos. = Positive; neg. = negative; HR = hazard ratio.
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vanced cancer to progress does not depend on a few but 
on several major functional molecular alterations.
 However, some limitations have to be considered. Our 
study cohort was relatively small and exposed to various 
types and lines of chemotherapy that may introduce bias. 
Moreover, undifferentiated CTC subpopulations that 
emerge from epithelial mesenchymal transition or cancer 
stem cells may have distinct patterns of gene expression, 
and therefore might have escaped our current detection 
methods. As a consequence for CTC separation and anal-
ysis, we have to target further tumor-associated antigens 
and also determine additional genes representing the va-
riety of metastatic spreading in order to illuminate the 
mutational heterogeneity of cancer.
 Conclusion 
 Our data suggest an independent prognostic value of 
CTC as identified by our method of magnetic bead selec-
tion using 2 common tumor surface markers, followed by 
PCR quantification of 5 key cancer-associated transcripts. 
Further investigation should help in establishing the role 
of CTC in clinical practice, especially as a parameter of 
(immediate) therapy response.
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